-
- Vidhya Kumar
- From the Ohio State University Davis Heart and Lung Research Institute, Columbus (V.K., W.A.H., S.V.R.); and Division of Endocrinology, Diabetes & Metabolism, Ohio State University, Columbus (W.A.H.).
-
- Willa A. Hsueh
- From the Ohio State University Davis Heart and Lung Research Institute, Columbus (V.K., W.A.H., S.V.R.); and Division of Endocrinology, Diabetes & Metabolism, Ohio State University, Columbus (W.A.H.).
-
- Subha V. Raman
- From the Ohio State University Davis Heart and Lung Research Institute, Columbus (V.K., W.A.H., S.V.R.); and Division of Endocrinology, Diabetes & Metabolism, Ohio State University, Columbus (W.A.H.).
書誌事項
- 公開日
- 2017-11
- DOI
-
- 10.1161/circimaging.117.005447
- 公開者
- Ovid Technologies (Wolters Kluwer Health)
この論文をさがす
説明
<jats:p>Cardiometabolic disease, spanning conditions such as obesity to type 2 diabetes mellitus with excess cardiovascular risk, represents a major public health burden. Advances in preclinical translational science point to potential targets across multiple organ systems for early intervention to improve cardiometabolic health. Validation in clinical trials and translation to care would benefit from in vivo diagnostic techniques that facilitate therapeutic advancements. This review provides a state-of-the-art, multimodality perspective spanning the multiple organ systems that contribute to cardiometabolic disease.</jats:p>
収録刊行物
-
- Circulation: Cardiovascular Imaging
-
Circulation: Cardiovascular Imaging 10 (11), 10-, 2017-11
Ovid Technologies (Wolters Kluwer Health)